Drug Profile
A3 adenosine receptor agonists companion diagnostic - Can-Fite BioPharma/Smart Assays
Alternative Names: A3AR agonists companion diagnostic - Can-Fite BioPharma/Smart Assays; CF 101 companion diagnostic - Can-Fite BioPharma/Smart Assays; CF 102 companion diagnostic - Can-Fite BioPharma/Smart Assays; Namodenoson companion diagnostic - Can-Fite BioPharma/Smart AssaysLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Can-Fite BioPharma; Smart Assays
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in liver cancer(Diagnosis) in Israel
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis(Diagnosis) in Israel
- 21 Apr 2014 Clinical in liver cancer (diagnosis) in Israel (unspecified route)